Basit öğe kaydını göster

Etanercept treatment in corticosteroid-dependent myasthenia gravis

dc.contributor.authorMERIGGIOLI, MN
dc.contributor.authorTuzun, Erdem
dc.contributor.authorLEURGANS, S
dc.contributor.authorCHRISTADOSS, P
dc.contributor.authorROWIN, J
dc.date.accessioned2021-03-02T22:47:02Z
dc.date.available2021-03-02T22:47:02Z
dc.date.issued2004
dc.identifier.citationROWIN J., MERIGGIOLI M., Tuzun E., LEURGANS S., CHRISTADOSS P., "Etanercept treatment in corticosteroid-dependent myasthenia gravis", NEUROLOGY, cilt.63, sa.12, ss.2390-2392, 2004
dc.identifier.issn0028-3878
dc.identifier.otherav_0eb21e3f-9262-472b-86df-a33131615aca
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/15417
dc.identifier.urihttps://doi.org/10.1212/01.wnl.0000147242.92691.71
dc.description.abstractThe authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.
dc.language.isoeng
dc.subjectNöroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectKLİNİK NEUROLOJİ
dc.titleEtanercept treatment in corticosteroid-dependent myasthenia gravis
dc.typeMakale
dc.relation.journalNEUROLOGY
dc.contributor.department, ,
dc.identifier.volume63
dc.identifier.issue12
dc.identifier.startpage2390
dc.identifier.endpage2392
dc.contributor.firstauthorID1791


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster